# Damona Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/damona-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Toronto, Canada
- Website: www.damonapharma.com
- Total disclosed funding: $5.5M
- Latest round: Seed (Sep 26, 2022)
- Investors on record: 3

## About

Based in Toronto, CA, and founded in 2022, Damona Pharmaceuticals Inc., f.k.a. Alpha Cog, a.k.a. Damona Pharmaceuticals is a pre-clinical pharmaceutical company founded by interim CEO Dr. Etienne Sibille and the Centre for Addiction and Mental Health (CAMH), discovering and developing small molecules for the treatment and prevention of cognitive symptoms in depression and other brain disorders. In September 2022, Damona Pharmaceuticals Inc. raised USD 5.5 million in seed funding co-led by Lumira Ventures and Noetic Fund, with participation from TIAP.

The company is developing AC-101, a preclinical stage pharmaceutical product for the treatment of cognitive symptoms and restoring normal life functions for underserved and understudied mental health and aging populations.

Damona Pharmaceuticals plans to use its proceeds from September 2022 funding to support the development of its lead therapeutic for the treatment of cognitive symptoms associated with depression and diseases of aging as well as early-stage development programs.

## Funding rounds

- Seed, Sep 26, 2022, $5.5M — TIAP, Noetic Fund, Lumira Ventures

## Investors

- TIAP — Seed
- Noetic Fund (https://capitalatlas.ai/funds/noetic-fund) — Seed
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Seed